Charles Crane, MD
Ophthalmology · South Orange, NJNPI 1710961917
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $60,286 of the $76,040 with a category attached, or 79.3%. Glaukos Corporation accounts for 84.2% of it on its own, with 26 other manufacturers making up the rest. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $226.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$64K
- Biotissue Holdings Inc.$3K
- AbbVie$3K
- Alcon$944
- Johnson & Johnson Surgical Vision, Inc.$893
- Bausch & Lomb Americas Inc.$753
- plus $3K from 21 others
Across 317 payments — averaging $1595.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$254K
- Glaukos Corporation$184K
- Novartis$32K
- Johnson & Johnson Surgical Vision, Inc.$30K
- Sight Sciences, Inc.$5K
- Bausch & Lomb Americas Inc.$1K
- plus $558 from 1 others
What the payments were for
- Consulting fees$60,28679%
- Travel & lodging$2,9434%
- Food & beverage$11,99716%
- Education$8151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 47 | $63,996 |
| Biotissue Holdings Inc. | 36 | $3,457 |
| AbbVie(2 entities) | 97 | $3,136 |
| Alcon | 19 | $944 |
| Johnson & Johnson Surgical Vision, Inc. | 11 | $893 |
| Bausch & Lomb Americas Inc. | 18 | $753 |
| Sight Sciences, Inc. | 17 | $661 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $280 |
| Dompe US, Inc. | 6 | $276 |
| Sun Pharmaceutical Industries Inc. | 6 | $204 |
| NEW World Medical,inc. | 2 | $173 |
| Novartis | 8 | $150 |
| Rxsight Inc | 3 | $148 |
| Tarsus Pharmaceuticals, Inc. | 5 | $147 |
| Oyster Point Pharma, Inc. | 9 | $144 |
| Amgen(2 entities) | 7 | $116 |
| Merz North America, Inc. | 5 | $110 |
| Kala Pharmaceuticals, Inc. | 5 | $74 |
| Aerie Pharmaceuticals, Inc. | 5 | $72 |
| Eyevance Pharmaceuticals LLC | 4 | $64 |
| Genentech USA, Inc. | 2 | $61 |
| Harrow Eye, LLC | 3 | $57 |
| Ocular Therapeutix, Inc. | 2 | $30 |
| Shire North American Group Inc | 2 | $29 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Thea Pharma Inc. | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$16,037
- iStent inject W$5,152
- Prokera$2,892
- AmnioGraft$2,892
- iDose$1,888
- Tecnis IOL$594
- iDoseTR$558
- MIEBO$369
- XIIDRA$369
- OMNI(R) SURGICAL SYSTEM (US)$340
- SION SURGICAL INSTRUMENT$340
- Clareon$287
- enVista MX60 IOL$242
- iStent$209
- iStent Infinite$194
- iS3-iStent infiniteTrabecular Micro-Bypass System Model iS3$187
- iStent infinite Trabecular Micro-Bypass System Model iS3$187
- iStent Inject Trabecular Micro-Bypass System$171
- Kahook Dual Blade$170
- Streamline Surgical System$170
How this compares
$76,040 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 121 | $108,546 |
| LumiganBimatoprost | 221 | $104,231 |
| RestasisCyclosporine | 90 | $82,727 |
| VyzultaLatanoprostene Bunod | 149 | $54,613 |
| CombiganBrimonidine Tartrate/Timolol | 109 | $39,312 |
| RocklatanNetarsudil Mesylat/Latanoprost | 69 | $29,601 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 69 | $18,280 |
| ProlensaBromfenac Sodium | 38 | $15,198 |
| Prednisolone Acetate | 462 | $14,175 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 78 | $13,870 |
| CequaCyclosporine | 16 | $11,785 |
| Ketorolac Tromethamine | 479 | $11,743 |
| Travoprost | 74 | $8,040 |
| RhopressaNetarsudil Mesylate | 18 | $7,960 |
| Cyclosporine | 26 | $7,590 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $3,136 | $233,280453 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $753 | $163,158270 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $72 | $37,56287 claims |
| AlconSimbrinza | $944 | $18,28069 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $280 | $15,19838 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $204 | $11,78516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in South Orange
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.